421 related articles for article (PubMed ID: 29623679)
1. Pregnancy Outcomes After Exposure to Certolizumab Pegol: Updated Results From a Pharmacovigilance Safety Database.
Clowse MEB; Scheuerle AE; Chambers C; Afzali A; Kimball AB; Cush JJ; Cooney M; Shaughnessy L; Vanderkelen M; Förger F
Arthritis Rheumatol; 2018 Sep; 70(9):1399-1407. PubMed ID: 29623679
[TBL] [Abstract][Full Text] [Related]
2. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol.
Clowse ME; Wolf DC; Förger F; Cush JJ; Golembesky A; Shaughnessy L; De Cuyper D; Mahadevan U
J Rheumatol; 2015 Dec; 42(12):2270-8. PubMed ID: 26523031
[TBL] [Abstract][Full Text] [Related]
3. Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol.
Clowse M; Fischer-Betz R; Nelson-Piercy C; Scheuerle AE; Stephan B; Dubinsky M; Kumke T; Kasliwal R; Lauwerys B; Förger F
Ther Adv Musculoskelet Dis; 2022; 14():1759720X221087650. PubMed ID: 35464812
[TBL] [Abstract][Full Text] [Related]
4. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study.
Mariette X; Förger F; Abraham B; Flynn AD; Moltó A; Flipo RM; van Tubergen A; Shaughnessy L; Simpson J; Teil M; Helmer E; Wang M; Chakravarty EF
Ann Rheum Dis; 2018 Feb; 77(2):228-233. PubMed ID: 29030361
[TBL] [Abstract][Full Text] [Related]
5. Minimal to no transfer of certolizumab pegol into breast milk: results from CRADLE, a prospective, postmarketing, multicentre, pharmacokinetic study.
Clowse ME; Förger F; Hwang C; Thorp J; Dolhain RJ; van Tubergen A; Shaughnessy L; Simpson J; Teil M; Toublanc N; Wang M; Hale TW
Ann Rheum Dis; 2017 Nov; 76(11):1890-1896. PubMed ID: 28814432
[TBL] [Abstract][Full Text] [Related]
6. Leflunomide use during pregnancy and the risk of adverse pregnancy outcomes.
Bérard A; Zhao JP; Shui I; Colilla S
Ann Rheum Dis; 2018 Apr; 77(4):500-509. PubMed ID: 29222350
[TBL] [Abstract][Full Text] [Related]
7. Certolizumab Pegol in Plaque Psoriasis: Considerations for Pregnancy.
Strain J; Leis M; Lee KO; Fleming P
Skin Therapy Lett; 2021 Mar; 26(2):1-5. PubMed ID: 33769772
[TBL] [Abstract][Full Text] [Related]
8. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients.
Förger F; Zbinden A; Villiger PM
Joint Bone Spine; 2016 May; 83(3):341-3. PubMed ID: 26617214
[TBL] [Abstract][Full Text] [Related]
9. Tocilizumab use in pregnancy: Analysis of a global safety database including data from clinical trials and post-marketing data.
Hoeltzenbein M; Beck E; Rajwanshi R; Gøtestam Skorpen C; Berber E; Schaefer C; Østensen M
Semin Arthritis Rheum; 2016 Oct; 46(2):238-245. PubMed ID: 27346577
[TBL] [Abstract][Full Text] [Related]
10. Evaluating the postmarketing experience of risperidone use during pregnancy: pregnancy and neonatal outcomes.
Coppola D; Russo LJ; Kwarta RF; Varughese R; Schmider J
Drug Saf; 2007; 30(3):247-64. PubMed ID: 17343431
[TBL] [Abstract][Full Text] [Related]
11. Safety of cetirizine in pregnancy.
Golembesky A; Cooney M; Boev R; Schlit AF; Bentz JWG
J Obstet Gynaecol; 2018 Oct; 38(7):940-945. PubMed ID: 29565188
[TBL] [Abstract][Full Text] [Related]
12. Lacosamide and pregnancy: Data from spontaneous and solicited reports.
Perucca P; Bourikas D; Voinescu PE; Vadlamudi L; Chellun D; Kumke T; Werhahn KJ; Schmitz B
Epilepsia; 2024 May; 65(5):1275-1284. PubMed ID: 38411300
[TBL] [Abstract][Full Text] [Related]
13. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
Tzanetakos C; Tzioufas A; Goules A; Kourlaba G; Theodoratou T; Christou P; Maniadakis N
Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey.
Vavricka SR; Spasojevic M; Rogler G; Schoepfer AM; Seibold F; Borovicka J; Frei P; Zeitz J; Greuter T; Manser C; Scharl M; Misselwitz B; Straumann A; Michetti P; Biedermann L;
Dig Dis; 2017; 35(5):423-432. PubMed ID: 28595194
[TBL] [Abstract][Full Text] [Related]
15. Prospectively-followed pregnancies in patients with inflammatory arthritis taking biological drugs: an Italian multicentre study.
Bazzani C; Scrivo R; Andreoli L; Baldissera E; Biggioggero M; Canti V; Gerosa M; Pontikaki I; Ramoni V; Trespidi L; Zatti S; Caporali R; Gorla R; Iannone F; Lojacono A; Meroni P; Montecucco C; Motta M; Sabbadini MG; Valesini G; Tincani A
Clin Exp Rheumatol; 2015; 33(5):688-93. PubMed ID: 26311348
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy.
Prieto-Peña D; Calderón-Goercke M; Adán A; Chamorro-López L; Maíz-Alonso O; De Dios-Jiménez Aberásturi JR; Veroz R; Blanco S; Martín-Santos JM; Navarro F; Gallego A; González-Suárez S; Conesa A; García-Valle A; Cordero-Coma M; Pardiñas-Barón N; Demetrio R; Calvo-Río V; Martínez-Taboada VM; Castañeda S; Hernández JL; González-Gay MA; Blanco R
Clin Exp Rheumatol; 2021; 39(1):105-114. PubMed ID: 33124565
[TBL] [Abstract][Full Text] [Related]
17. A rheumatoid arthritis patient with delivery who started certolizumab pegol and tacrolimus during pregnancy.
Ito S; Ishikawa H; Kato R
Mod Rheumatol Case Rep; 2022 Jan; 6(1):6-9. PubMed ID: 34477867
[TBL] [Abstract][Full Text] [Related]
18. Continuous Anti-TNFα Use Throughout Pregnancy: Possible Complications For the Mother But Not for the Fetus. A Retrospective Cohort on the French National Health Insurance Database (EVASION).
Luu M; Benzenine E; Doret M; Michiels C; Barkun A; Degand T; Quantin C; Bardou M
Am J Gastroenterol; 2018 Nov; 113(11):1669-1677. PubMed ID: 29961771
[TBL] [Abstract][Full Text] [Related]
19. Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population.
Weinblatt ME; Fleischmann R; van Vollenhoven RF; Emery P; Huizinga TW; Cutolo M; van der Heijde D; Duncan B; Davies O; Luijtens K; Dougados M
Arthritis Res Ther; 2015 Nov; 17():325. PubMed ID: 26568428
[TBL] [Abstract][Full Text] [Related]
20. Disease-modifying anti-rheumatic drug use in pregnant women with rheumatic diseases: a systematic review of the risk of congenital malformations.
Baldwin C; Avina-Zubieta A; Rai SK; Carruthers E; De Vera MA
Clin Exp Rheumatol; 2016; 34(2):172-83. PubMed ID: 26940667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
